Progression-free survival with the ICE regimen in refractory RAS/BRAF wild-type and MSS mCRC patients. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This ...

Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial. Secondary cytoreduction followed by ...